Vical (NASDAQ: DBVT) and DBV TECHNOLOGIE/S (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Valuation & Earnings

This table compares Vical and DBV TECHNOLOGIE/S’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vical $13.82 million 2.19 -$12.96 million ($1.01) -1.38
DBV TECHNOLOGIE/S $13.45 million 100.98 -$166.93 million ($3.37) -7.07

Vical has higher revenue and earnings than DBV TECHNOLOGIE/S. DBV TECHNOLOGIE/S is trading at a lower price-to-earnings ratio than Vical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vical and DBV TECHNOLOGIE/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vical -207.71% -33.70% -28.93%
DBV TECHNOLOGIE/S N/A N/A N/A

Risk and Volatility

Vical has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, DBV TECHNOLOGIE/S has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Institutional and Insider Ownership

45.8% of Vical shares are owned by institutional investors. Comparatively, 44.7% of DBV TECHNOLOGIE/S shares are owned by institutional investors. 4.6% of Vical shares are owned by insiders. Comparatively, 15.3% of DBV TECHNOLOGIE/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Vical and DBV TECHNOLOGIE/S, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vical 0 0 1 0 3.00
DBV TECHNOLOGIE/S 0 2 7 0 2.78

Vical presently has a consensus target price of $4.00, suggesting a potential upside of 187.77%. DBV TECHNOLOGIE/S has a consensus target price of $40.14, suggesting a potential upside of 68.60%. Given Vical’s stronger consensus rating and higher probable upside, analysts clearly believe Vical is more favorable than DBV TECHNOLOGIE/S.

Summary

DBV TECHNOLOGIE/S beats Vical on 7 of the 13 factors compared between the two stocks.

Vical Company Profile

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.